Ibogaine

MINDCURE Provides Update on Studies and Clinical Trials

Retrieved on: 
星期四, 十一月 4, 2021
Desire, Good, OTCQX, Research, Technology, USD, LinkedIn, GLP, Good laboratory practice, Ketamine, Ethics, MDMA, IP, Twitter, Advertising, CSE, Psychotherapy, FDA, Desire Projects, Ibogaine, Single-frequency network, Sandstone, GMP, Social media, Plan, Marketing, Company, Instagram, Phrase, Mental health, COVID-19, Letter, Awareness, Multimedia, Program, News, Solution, Female, Good manufacturing practice, FRA, MVP, Pharmaceutical industry, Public relations, Risk management

MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.

Key Points: 
  • MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022.
  • The material will initially be used for broad cardiac and neurologic screens, with the potential to conduct in-depth behavioral studies.
  • This program has been identified as MSYNTH-001, and the Company expects results from the first studies during the first quarter of 2022.
  • In addition to advancing the scale of its synthetic ibogaine program, MINDCURE continues to explore options for drug pipeline expansion.

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

Retrieved on: 
星期三, 十一月 3, 2021
Psilocybin, Partnership, Orphan drug, Research, DMT, Inflammation, Ischemia, Microdosing, Substance abuse, RVV, MN, MDMA, Drug development, Organ transplantation, CSE, Patient, CGMP, FDA, Holding, Ibogaine, Infection, Autoimmune hepatitis, LSD, Ketamine, Reperfusion injury, OTCQB, Liver disease, Company, Lysergic acid diethylamide, Lists of diseases, Mental health, CEO, Trial of the century, COVID-19, Skin, IND, Acquisition, N, Therapy, GLOBE, Mescaline, Disorder, Plasma, Pharmaceutical industry

PharmaTher is currently conducting IND-enabling research studies with MicoDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022.

Key Points: 
  • PharmaTher is currently conducting IND-enabling research studies with MicoDose-MN, a patent-pending biocompatible and biodegradable gelatin methacryloyl microneedle patch, to deliver psilocybin to support an IND application with the FDA for clinical studies in 2022.
  • Research results with MicroDose-MN for psilocybin will be made available in November 2021.
  • Our microneedle patch technologies aim to become a next generation delivery system for psychedelics for various indications and healthcare environments.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics

Retrieved on: 
星期一, 十一月 1, 2021
Research, DMT, Microdosing, MDMA, MN, Partnership, CSE, Patient, Terasaki, CGMP, FDA, Psilocybin, Ibogaine, Infection, LSD, Ketamine, OTCQB, Company, Lysergic acid diethylamide, Mental health, CEO, Betaine, Trial of the century, Skin, GLOBE, Mescaline, Plasma, Vaccine, Pharmaceutical industry, Medical device

TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today provides an update on the ongoing research studies with its novel microneedle (MN) patch as a next generation delivery technology for psychedelics, including ketamine, psilocybin, 3,4-methylenedioxy-methamphetamine (MDMA), lysergic acid diethylamide (LSD), and N, N-dimethyltryptamine (DMT).

Key Points: 
  • TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today provides an update on the ongoing research studies with its novel microneedle (MN) patch as a next generation delivery technology for psychedelics, including ketamine, psilocybin, 3,4-methylenedioxy-methamphetamine (MDMA), lysergic acid diethylamide (LSD), and N, N-dimethyltryptamine (DMT).
  • PharmaTher is proceeding with its IND-enabling studies and manufacturing scale-up for cGMP microneedle patches for its expected clinical studies in 2022.
  • We are nearing completion of our research programs in validating the utility of our microneedle patch delivery technologies for psychedelics, derisking our plans in advancing the completion of our IND-enabling studies to support future clinical studies and partnering opportunities, said Fabio Chianelli, CEO of PharmaTher.
  • PharmaTher is currently advancing an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics and infectious disease treatments.

MindMed to Present at Web Summit on Future of Mental Health

Retrieved on: 
星期一, 十一月 1, 2021
NEO Exchange, Compliance, Research, DMT, Technology, EDGAR, Industry, MMQ, MDMA, Web Summit, History, NASDAQ, SEDAR, View, Psilocybin, Ibogaine, U.S. Securities and Exchange Commission, Mark (given name), LSD, Nature, Medicine, Risk, Company, NEO, Mental health, Clinical trial, DE, Multimedia, News, Pharmaceutical industry

Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".

Key Points: 
  • Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".
  • The session will touch on MDMA dosing, psychedelic precision medicine, LSD neutralising and similar themes around the future for specialised mental health treatment.
  • Web Summit is an annual technology conference that brings together the people and companies redefining the global tech industry.
  • Politico calls it the "world's premier tech conference", while The Atlantic says that Web Summit is "where the future goes to be born".

Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and 'Psychedelic Concierge' Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health

Retrieved on: 
星期四, 十月 14, 2021
Risk, Pharmacology, Telehealth, FWB, Adrienne Arsht Center for the Performing Arts, State University of New York, Korea University, Lists of diseases, SUNY, State University of New York Upstate Medical University, Ketamine, State university system, Ta' Braxia Cemetery, CSE, OTC, Depression, Drug prohibition law, Ibogaine, PTSD, Guangzhou Medical University, Meditation, Addiction, The New York Times, FDA, Multimedia, News, Removal of cannabis from Schedule I of the Controlled Substances Act, University, CDSA, Health Canada, Clarivate, Forward-looking statement, Company, National Basketball Association, Psychiatry, College, Transitive dependency, Person, Controlled Drugs and Substances Act, Psilocybin, Anxiety, Euro-Excellence Inc v Kraft Canada Inc, Disorder, Rapids, Consciousness, Pharmaceutical industry, Audit

As a world-leading depression researcher, Dr. Roger McIntyre has been named one of the world's most influential scientific minds by Clarivate for seven consecutive years.

Key Points: 
  • As a world-leading depression researcher, Dr. Roger McIntyre has been named one of the world's most influential scientific minds by Clarivate for seven consecutive years.
  • Lamar Odom is a two-time National Basketball Association champion, Olympic gold medalist, New York Times bestselling author, and mental health advocate.
  • Zappy Zapolin is the co-founder and executive chairman of KetaMD , a developing telemedicine platform that provides at-home medical ketamine treatments.
  • "Dr. McIntyre and I are very mission-aligned on the untapped benefits of psychedelics in the treatment of many mental health conditions," says Zappy Zapolin, co-founder of KetaMD and director of Reborn.

On November 2nd, Detroiters Can Vote Yes on Proposal E To Decriminalize Plant Based Medicine

Retrieved on: 
星期五, 十月 8, 2021
People, Cocaine, PTSD, Heroin, Hydrocodone/paracetamol, Ibogaine, Lists of diseases, Oxycodone, Population, Plant, Detroiters, Cannabis, FDA, Fentanyl, Depression, Psilocybin, Opioid, Proposal, Medicine, Anxiety, Congress, Research, Drug, Pharmaceutical industry

For decades our communities suffered at the hands of misguided drug laws and harsh prison sentencing that results in disproportionate prison population.

Key Points: 
  • For decades our communities suffered at the hands of misguided drug laws and harsh prison sentencing that results in disproportionate prison population.
  • The "People For Healthy Choices," a local advocacy group is asking Detroit Voter's to take a stand and Vote Yes for Proposal E to decriminalize plant based medicine.
  • Voting yes to proposal E makes it easy heal and decriminalize plant based medicine.
  • On November 2nd, Vote yes for Proposal E, makes it easy!

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

Retrieved on: 
星期四, 九月 30, 2021
News, MGH Institute of Health Professions, Nature, Harvard Medical School, Clinical trial, Berkshire Partners, Compliance, McLean Hospital, Risk, Cresco Labs, LSD, Supervisory board, NASDAQ, Founder CEO, U.S. Securities and Exchange Commission, Mass, Multimedia, Advisory board, Board of directors, Ibogaine, Illusion, Young invincibles, MDMA, Board, DE, CEO, NEO Exchange, Company, Trustee, Merz Pharma, SEDAR, Mass General Brigham, DMT, View, Research, MMQ, Organization, NEO, Psilocybin, EDGAR, Industry, Management, Pharmaceutical industry

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.

Key Points: 
  • Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies.
  • Effective September 29, 2021, Mr. Bruce Linton stepped down from the Company's board of directors in order to make room for the appointment of Ms. Vallone and Mr. Krebs.
  • MindMed Chair Perry Dellelce said,"We are extremely happy to welcome Carol and Andreas to the Board.
  • The appointment of Mr. Krebs and Ms. Vallone is subject to regulatory approval.

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

Retrieved on: 
星期三, 九月 29, 2021
UNC School of Medicine, Nature, Duke University, Michael Hooker, University, Mental health, Stanford University, Johns Hopkins University, Cell, Psychiatry, DARPA, Industry, University of North Carolina at Greensboro, Biotechnology, News, Coronavirus Scientific Advisory Board (Turkey), Compliance, National, School, U.S. Securities and Exchange Commission, Multimedia, Ibogaine, Department of Pharmacology, University College London, NEO Exchange, Knowledge, Ultra-large-scale systems, MMQ, History, EDGAR, Clinical trial, Risk, NASDAQ, New York University, Company, SEDAR, National Institute, Brain, UNC, Neuroscience, NEO, Doctor of Philosophy, Massachusetts General Hospital, Department, LSD, Patient, MD, MDMA, DE, DMT, View, Research, Psilocybin, Hallucination, Pharmaceutical industry

He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.

Key Points: 
  • He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.
  • MindMed CEO Robert Barrow said, "We are thrilled to welcome Dr. Roth to our Scientific Advisory Board.
  • MindMed's Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development.
  • Members represent institutions such as Johns Hopkins University, New York University Langone Health, Duke University, the National Institutes of Health, Stanford University, and Massachusetts General Hospital.

Psycheceutical, Inc. Expands Executive Team with Announcement of New Advisory Board Appointments

Retrieved on: 
星期二, 九月 28, 2021
Janus, USP, Dizziness, Ketamine, 795, Autism, Peripheral neuropathy, Stroke, FDA, Headache, Ibogaine, PCT, Nausea, American Board of Commissioners for Foreign Missions, Mental Health Awareness Month, Toxicity, American Academy, Growth, Pain, American Academy of Neurology, Stomach, Liver, Psychiatry, Safety, Psilocybin, Industry, Seizure, Fibromyalgia, Medical device, Pharmaceutical industry

Dr. Aung-Din will advise Psycheceutical as the company advances its patented technology, the NeuroDirect delivery system.

Key Points: 
  • Dr. Aung-Din will advise Psycheceutical as the company advances its patented technology, the NeuroDirect delivery system.
  • This delivery system allows for smaller doses, improved efficacy of the active compound, and immediate response in minutes.
  • Dr. Aung-Din, a holder of 13 US and foreign patents, treats neurological and neuropsychiatric conditions in adults and children.
  • "We are honored to welcome Dr. Aung-Din and Dr. Kutzko to our fast-growing team," said PsycheceuticalCEO Chad Harman.

MindMed to present at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
星期二, 九月 28, 2021
News, Nature, Clinical trial, Compliance, Risk, LSD, Interview, Conference, NASDAQ, U.S. Securities and Exchange Commission, Multimedia, Ibogaine, MDMA, DE, NEO Exchange, Company, SEDAR, DMT, View, Research, MMQ, History, NEO, Psilocybin, EDGAR, Industry, Pharmaceutical industry

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.

Key Points: 
  • MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
  • Forward-looking information in this news release include, but are not limited to, statements regarding MindMed's participation at the Benzinga Healthcare Small Cap Conference.